SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel ($INTC) is surging after a strong earnings report, with revenue and EPS exceeding expectations, sparking optimism about its turnaround. Community members are discussing the potential for a short squeeze and future growth, fueled by government investment and new strategic directions. Positive commentary surrounds CEO Lip Bu Tan, with many believing he is steering the company toward a comeback in the semiconductor industry.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending following news of its biometric system deployment at Chicago O'Hare International Airport. Community members are speculating about further airport expansions and potential TSA contracts, contributing to bullish sentiment. Discussions also involve the stock's potential for a short squeeze and comparisons to other AI stocks.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

QBTS is trending amid speculation and conflicting reports about potential government investment in quantum computing companies, driving high trading volume. Community discussions revolve around the accuracy of news reports and the potential impact of government involvement on the sector. Some traders believe QBTS could benefit significantly due to its position in the quantum optimization market.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is trending amid community discussions around potential rallies and comparisons to other meme coins like DOGE and BONK.  Investors are weighing the potential for future growth, while also debating its long-term viability.  Some users highlight the importance of community strength and burns, while others express skepticism.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending as investors discuss its potential following Intel's strong earnings, highlighting the increasing demand for AI compute. Community members are weighing in on the recent pullback, with some seeing it as a buying opportunity, while others remain cautious about the broader market volatility. Positive sentiment is fueled by the company's AI cloud infrastructure and partnerships, including its autonomous vehicle subsidiary Avride.

Deckers Outdoor Corp. engages in the business of designing, marketing, and distributing footwear, apparel, and accessories developed for both everyday casual lifestyle use and high performance activities. It operates through the following segments: UGG Brand, HOKA Brand, Teva Brand, Sanuk Brand, Other Brands, and Direct-to-Consumer. The UGG Brand segment offers a line of premium footwear, apparel, and accessories. The HOKA Brand segment sells footwear and apparel that offers enhanced cushioning and inherent stability with minimal weight, originally designed for ultra-runners. The Teva Brand segment focuses on the sport sandal and modern outdoor lifestyle category, such as sandals, shoes, and boots. The Sanuk Brand segment originated in Southern California surf culture and has emerged into a lifestyle brand with a presence in the relaxed casual shoe and sandal categories. The Other Brands segment includes the Koolaburra by UGG brand. The Direct-to-Consumer segment consists of retail stores and e-commerce websites. The company was founded by Douglas B. Otto in 1973 and is headquartered in Goleta, CA.

Deckers Outdoor Corp.

Deckers Outdoor is trending as the community analyzes recent quarterly earnings and future sales estimates, with some investors seeing a buying opportunity despite revised revenue outlooks. Community members are actively debating the impact of tariffs, consumer spending, and brand growth, especially for HOKA and UGG. Some traders are highlighting technical indicators and historical support levels to evaluate potential price movements.

Newmont Corp. engages in the exploration and acquisition of gold properties, containing copper, silver, lead, zinc or other metals. It operates through the following geographical segments: Canada, Mexico, Suriname, Argentina, Peru, Australia, Papua New Guinea, Ghana, and U.S. The company was founded by William Boyce Thompson on May 2, 1921 and is headquartered in Denver, CO.

Newmont Corp

Newmont is trending as investors digest recent earnings and a drop in gold production, despite beating expectations. The community is discussing the CEO's performance on the earnings call and debating whether the stock's reaction is an overreaction, considering the surge in gold prices. Some traders are weighing the potential for share buybacks and dividend increases, while others consider switching to physical gold.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

PEPE is trending amid volatile market conditions, with community members actively discussing dip-buying strategies and potential recovery points. The conversation includes comparisons to other meme coins like SHIB and DOGE, while some traders are exploring new, low market cap opportunities within the memecoin space. Despite recent price drops, some remain optimistic about a potential rebound and long-term growth.

$BALLIN is the perfect meme for everyone showing up every single day.  To be BALLIN, you gotta B-All-In.  The meaning to B All In doesn't only apply to the funds you invest.  It's about dedication.   The countless hours of research.   The endless raiding and working for your bags.  Not knowing how to quit while everyone is telling you you're wrong.  It's about believing in something.  Keep $BALLIN

B All In

B All In ($BALLIN) is gaining traction, particularly within the Phantom Wallet community, with users highlighting its potential for significant gains. Community members are focused on accumulating the token, emphasizing a 'lifestyle' centered around success and profitability. The conversation suggests a strong, bullish sentiment around $BALLIN, associating it with 'early rocket mode' and 'moon vibes.'

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

WBD is trending amid ongoing speculation of a potential buyout, with community chatter focusing on the possibility of a bidding war and the potential offer price. Discussions include potential buyers like Paramount, Netflix, and Comcast, as well as the strategic implications of a deal on the media landscape. Community members are actively debating the likelihood of a deal, potential offer prices, and the impact on the stock's value.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

X4 Pharmaceuticals (XFOR) Upgraded to Strong Buy: What Does It Mean for the Stock?

X4 Pharmaceuticals (XFOR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

X4 Pharmaceuticals (XFOR) announced on Wednesday that it will reduce its workforce by 50% as part of a strategic restructuring.The workforce reduction is expected to result in annualized cost savings of approximately $13 million, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.x4pharma.com/news-releases/news-release-details/x4-pharmaceuticals-announces-restructuring-business-operations">said.</a> The strategic restructuring is aimed at aligning resources to complete the late-stage trial of Mavorixafor in patients with moderate and severe chronic neutropenia, it added.Shares of the company traded 0.5% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/XFOR">XFOR stock</a> rose from 'bearish' to 'neutral' territory over the past 24 hours, while message volume stayed at ‘extremely low’ levels.The Boston-headquartered firm announced that Chief Legal and Compliance Officer Natasha Thoren, Chief Operating Officer Mary DiBiase, and Chief Commercial Officer Mark Baldry will be exiting the company as part of the workforce reduction. Chief Medical Officer Christophe Arbet‑Engels, meanwhile, is resigning for personal reasons, it added.“Over the coming weeks, we plan to continue to drive operational efficiencies, consolidate resources, and strengthen our leadership structure. With these changes, we expect to be well-positioned to become a world‑class hematology company, beginning with the advancement of mavorixafor into chronic neutropenia,” said Executive Chairman Adam Craig.The company also appointed its President, John Volpone, as the COO, and he will now oversee day‑to‑day operational management and business execution in his expanded role. Craig, meanwhile, will oversee clinical development.The company’s Mavorixafor is marketed as Xolremdi in the U.S. for the treatment of people aged 12 years and older with WHIM syndrome — a rare, primary immunodeficiency disorder that impairs white blood cell movement from the bone marrow to the bloodstream. The company is now evaluating additional uses of Mavorixafor and is conducting a global, pivotal late-stage clinical trial in people with certain chronic neutropenic disorders. Neutropenia is characterized by an abnormally low number of neutrophils, a type of white blood cell essential for fighting bacterial and fungal infections.XFOR stock is down by about 85% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/astrazeneca-says-asthma-drug-failed-trial-in-smokers-disease/chDGnwkRd64">AstraZeneca Says Asthma Drug Failed Trial In Smoker’s Disease</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

X4 Pharma To Halve Headcount Amid Efforts To Complete Neutropenia Trial

The workforce reduction is expected to result in annualized cost savings of approximately $13 million, the company said.

Equity

The workforce reduction is expected to result in annualized cost savings of approximately $13 million, the company said.


X4 Pharmaceuticals (XFOR) on Wednesday announced the closing of an upsized private placement of over 11 million shares of common stock and pre-funded warrants to purchase nearly 49 million shares of common stock for total offering proceeds of $85 million.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.x4pharma.com/news-releases/news-release-details/x4-pharmaceuticals-announces-closing-upsized-85-million-private">said</a> that the originally announced offering of $60 million was increased to allow for the inclusion of an investor who had a pre-existing investment right.<a href="https://stocktwits.com/symbol/XFOR">X4</a> intends to use the net proceeds from the offering for continued development towards a potential additional approval of Mavorixafor in chronic neutropenia, in addition to the commercialization of the drug for the treatment of WHIM syndrome.On Stocktwits, retail sentiment around the stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:631/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_13_at_9_57_21_AM_png_cea6672fbd.webp" alt="XFOR's Sentiment Meter and Message Volume as of 9:55 a.m. ET on Aug. 13, 2025 | Source: Stocktwits" width="631" height="61"><figcaption>XFOR's Sentiment Meter and Message Volume as of 9:55 a.m. ET on Aug. 13, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism about the placement and the additional funding.<stembedurl>https://stocktwits.com/Sir_Falstaff/message/624932917</stembedurl>However, another user opined that the stock would trade 200% higher if the news were that positive.<stembedurl>https://stocktwits.com/FreedoniaT/message/624925751</stembedurl>H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm's price target for the XFOR stock to $3.50 from $7 and kept a ‘Buy’ rating on the shares, according to The Fly.The firm updated the company's model to reflect the second-quarter (Q2) report and the private placement. The capital raised strengthens the balance sheet and aids in meeting the Hercules Loan covenant obligations, the analyst told investors in a research note.X4 on Tuesday announced that its President and Chief Executive Officer, Paula Ragan, and Chief Financial Officer Adam Mostafa have stepped down from their respective roles.X4 Board of Directors appointed Adam Craig as Executive Chair, John Volpone as President, and David Kirske as Chief Financial Officer, effective immediately.XFOR stock is down 86% this year and 83% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ppi-report-wall-street-awaits-wholesale-inflation-data-for-cues-fed-rate-cut/chrCQjNRd9J">PPI Report: Wall Street Awaits Wholesale Inflation Data For Further Cues On Fed’s Rate Path Ahead</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

X4 Pharmaceuticals Stock Rises On Closing Of Upsized Offering, But Brokerage Lowers Price Target

The company said that the originally announced offering of $60 million was increased to $85 million to allow for the inclusion of an investor who had a pre-existing investment right.

X4 Pharmaceuticals Unveils Corporate Presentation for Investors

X4 Pharmaceuticals (XFOR) has shared an update. X4 Pharmaceuticals, Inc. has recently made their latest corporate presentation available to the pub...

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that...

Commit To Buy X4 Pharmaceuticals At $1, Earn 48.2% Annualized Using Options

Investors considering a purchase of X4 Pharmaceuticals Inc (XFOR) shares, but tentative about paying the going market price of 1.40/share, might benefit from considering selling puts among the...

X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences

BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that...

X4 Pharmaceuticals on the Brink: The Race Against Nasdaq Delisting and Investor Confidence

X4 Pharmaceuticals (XFOR) has disclosed a new risk, in the Share Price & Shareholder Rights category. X4 Pharmaceuticals currently faces the risk o...

Q4 2023 X4 Pharmaceuticals Inc Earnings Call Transcript

Recap: X4 Pharmaceuticals Q4 Earnings

X4 Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. The firm is focused on mavorixafor which is being marketed in the U.S. under the trade name xolremdi. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.

XFOR
X4 Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest XFOR News

XFORX4 Pharmaceuticals Inc